The bull case is that the share price is very unlikely to fall below 4c. Record revenue does not translate into receivership. Positive cash flow and increasing revenue does however suggest that interest in this stock will increase. I know you don't believe it, but the numbers before Covid were encouraging, and the numbers for this quarter are equally exciting. The large number of shares on issue will substantially repress a price rise, but patience favours the older, wiser and more polite. Stay awake or else awaken to a new dawn.
- Forums
- ASX - By Stock
- CTV
- EN1 Renaissance
EN1 Renaissance, page-17
-
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CTV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online